The Oncologist turns thirty
The Oncologist is completing its third decade bringing academic oncology to daily practice. When it was conceived by Marty and Ann Murphy with Bruce Chabne
Related Articles
Acalabrutinib Regimen Demonstrates Combinatorial Benefit in MCL
Tycel Phillips, MD, questioned how the regimen of acalabrutinib, bendamustine, and rituximab would compare with taking the drugs separately in mantle cell lymphoma.
Rathmell steps down at NCI as Trump team considers candidates to replace her Wafik El-Deiry, Harvey Risch have been interviewed – The Cancer Letter
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and…
Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations
The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.
Dexamethasone Plus Physical Activity May Reduce Cancer-Related Fatigue
Combining aerobic and resistance-based physical activity with dexamethasone may improve quality of life and reduce the effects of fatigue.
Fill | SSO 2025 Surgical Oncology Bowl
To join a team for the 2025 SurgOnc Bowl, please complete the following questionnaire. For more information and the rules of engagement, please visit this…
The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome
The determination of unbiased cancer risk estimates in hereditary breast and ovarian cancer syndrome (HBOC) poses several challenges. The article by Katona and colleagues is…
Dana-Farber Brigham Cancer Center Recognized for Exceptional Outcomes in Adult Donor Stem Cell Transplants for Fifth Consecutive Year
Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.
MDS highlights from ASH 2024
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses his key myelodysplastic syndrome (MDS) highlights from this year’s ASH meeting.…
Kim Evaluates New Regimens for EGFR+ Lung Cancer
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and…
RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma
RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.